Protagonist Therapeutics, Inc.PTGXNASDAQ
LOADING
|||
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | 8.01% |
| Q2 2025 | 3.18% |
| Q1 2025 | 2.83% |
| Q4 2024 | -2.96% |
| Q3 2024 | 7.31% |
| Q2 2024 | -0.63% |
| Q1 2024 | 16.73% |
| Q4 2023 | -5.76% |
| Q3 2023 | -7.59% |
| Q2 2023 | 21.03% |
| Q1 2023 | -8.26% |
| Q4 2022 | 17.64% |
| Q3 2022 | -26.61% |
| Q2 2022 | -4.70% |
| Q1 2022 | -7.52% |
| Q4 2021 | 6.27% |
| Q3 2021 | 34.79% |
| Q2 2021 | 9.35% |
| Q1 2021 | 24.58% |
| Q4 2020 | 25.83% |
| Q3 2020 | -21.04% |
| Q2 2020 | 7.93% |
| Q1 2020 | 17.96% |
| Q4 2019 | -7.99% |
| Q3 2019 | -10.65% |
| Q2 2019 | 55.54% |
| Q1 2019 | -12.66% |
| Q4 2018 | 17.32% |
| Q3 2018 | -31.52% |
| Q2 2018 | 15.40% |
| Q1 2018 | 31.08% |
| Q4 2017 | 4.98% |
| Q3 2017 | -6.99% |
| Q2 2017 | 6.43% |
| Q1 2017 | 27.87% |
| Q4 2016 | 58.66% |
| Q3 2016 | -2.37% |
| Q2 2016 | 1.26% |
| Q1 2016 | 34.15% |
| Q4 2015 | 32.77% |